In order to compare the effects of RALA and RALB loss across a broader group of TNBC and HER2+ BC models, we next used RNAi to transiently knock down the RALs in the TNBC cell lines (MDA-MB-231, BT-549, and MDA-MB-468), HER2+ lines (SKBR3 and MDA-MB-453), and a HER2-overexpressing luminal B line (BT-474) [53,54]. This evidence concerns the gene RALB and breast cancer.